Female Pelvic Implants Market is Poised to Exhibit A Moderate 2.8% CAGR through 2027

Female pelvic implants are surgically inserted in the vagina to treat disorders such as pelvic organ prolapse and stress urinary incontinence. These disorders are responsible for affecting the life of women to a great extent and are prevalent mostly in the older generation. The option available for treating the issue is surgical repair with or without prosthetic implants. The market is popular in different regions of the world, as this is the only available treatment option for POP and SUI. The main products involved in the implantation process are vaginal mesh implants, vaginal grafts, vaginal slings and tapes. The global female pelvic implants market registered a market value of over US$ 230 Mn in 2017, which is expected to reach a value of over US$ 300 Mn by the end of 2027. The market is anticipated to witness a sluggish CAGR of 2.8% during the forecast period.

Market Dynamics

The female pelvic implants market is projected to witness a downfall and grow at a sluggish rate, marking a few issues that are limiting the growth of market. The major issue behind the restricted growth of the market pertains to complications that are associated with female pelvic implants. The surgeries that have taken place in the past have resulted in many health related issues like mesh erosion, infections etc. However there has been a shift of countries towards the value based healthcare model, which may help the female pelvic implants market. The governments and regulatory bodies of various countries are adopting various cost-containment measures to reduce the healthcare burden, especially in developed economies. This shift from volume- to value-based system is driven by various measures taken by governments, providers, payers and life sciences companies, which include outcome-based pricing, profit and risk sharing, price control and competitive tendering. This may have a positive impact on the market in the coming years.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-3422

Segmental Outlook

China is expected to be an attractive region in the global market for female pelvic implants. According to the forecast presented in this report, China will register a CAGR of 4.7% during the forecast period. However, in terms of market value, North America is anticipated to reach over US$ 80 Mn by the end of 2027. The growth of the various regional female pelvic implants markets is mainly driven by the rising geriatric population and a rise in need for optimal methods to treat pelvic organ prolapse.

In terms of indication type, stress urinary incontinence has a higher market share than pelvic organ prolapse. SUI is expected to hold a market value of over US$ 190 Mn by the end of 2027, growing at a CAGR of 3.6% during the forecast period. There is a significant rise in the rate of women suffering from SUI worldwide.

Competitive Scenario

With the rapidly changing dynamics of the female pelvic implants market, many companies are hesitating in taking risks. Manufacturers in the global market have faced over 650 lawsuits alleging a host of painful device related injuries. Such complications during the process of implants have resulted in many major companies exiting the market. There is however, hope for market players in developing regions where implant procedures are still prevalent. The companies who have exited the global market include Betatech, AMS, Promedon, Aspide Medical etc. On the other hand, companies that continue to prevail in the global market include Coloplast, Boston Scientific, PFM Medical, Ethicon, etc.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-3422

The upcoming years will show whether the various legislations and product developments will come up as a savior for the remaining players in the global female pelvic implants market.

Vulvodynia Treatment Market to Surpass US$ 8,091.6 Mn by 2028

Future Market Insights (FMI) has published a new research report on vulvodynia treatment market. The report has been titled, “Vulvodynia Treatment Market: Global Industry Analysis 2013 – 2017 and Opportunity Assessment 2018 – 2028.”  The report states that a recent Harvard study showed that there are approximately 6 million American women who are suffering from vulvodynia. Over 60% of patients’ report of visiting three or more health care providers for diagnosis and an astonishing 40% of patients remain undiagnosed. This study also reported that 40% of women with painful symptoms did not even seek medical care. Associations such as the National Vulvodynia Association (NVA) are playing a vital role in spreading awareness regarding Vulvodynia treatment. The NVA announced the launch of “Indivisible: Breaking the Silence”, a campaign empowering women with vulvodynia to break their silence and improve the path to diagnosis and treatment.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-4985

In order to cater to the need of the growing number of patients, companies are looking out for treatments and drugs that can subside the pain related to vulvodynia. Towards this, they are investing in research and development and mergers and acquisitions. For instance, in January 2016, Merck & Co. Inc., acquired IOmet Pharma Ltd., a privately held U.K.-based drug discovery company focused on the development of innovative medicines for the treatment of cancer. The other leading companies operating in the market are Eli Lilly and Company, AstraZeneca Plc., GlaxoSmithKline Plc., Pfizer Inc., Johnson & Johnson Services, Inc., and Allergan plc, among others.

According to the report, the global vulvodynia treatment market is expected to register a CAGR of 6.1% over the forecast period of 2018 and 2028. The market was worth US$ 4,261.2 Mn in 2017 and is expected to rise to a valuation of US$ 8,091.6 Mn by the end of 2028.

Growing Adoption to Augur Well for Global Market Revenue Growth

The swelling number of patients suffering from vulvodynia and harsh nature of chronic vulvar pain have led to the adoption of early diagnosis and treatment. The adequate results of medical treatments such as drugs, injections and creams have increased the preference for medication to treat vulvodynia. Furthermore, increasing adoption of medicinal treatments of vulvodynia has resulted in an increase in the sales of hormones, local anesthetics, and antidepressants. Additionally, promising compensation policies in most of the developed countries are also expected to act as a value driver to the growth of the global vulvodynia treatment market. On the other hand, the growing prevalence of the vulvodynia disease among women across the globe is a core factor that is pushing the growth of the vulvodynia treatment market. Vulvodynia is a very common disease in the United States and across the globe. Nevertheless, the ailment remains underdiagnosed or in some cases also incompetently treated.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-4985

Lethargic Research and Development for Vulvodynia Treatment Drugs to Slow Down Market Growth

Owing to the absenteeism of detailed information by patients, ignorance of the cause of vulvar pain, and satisfactory results of anticonvulsants and tricyclic antidepressants, researchers are unable to unveil the exact cause of vulvodynia and thereby the R&D on vulvodynia drugs is limited. After anticonvulsants and tricyclic antidepressants, only serotonin and norepinephrine reuptake inhibitors (SNRIs) drugs have showed positive results. Furthermore, if observed, the research and development for vulvodynia treatment is also in a very sluggish phase.

Varicella Zoster Infection Treatment Market to Reach a Valuation of US$ 1,969.1 Mn By 2027

Future Market Insights (FMI) has published a new report on the varicella zoster infection treatment market titled “Varicella Zoster Infection Treatment Market: Global Industry Analysis 2012 – 2016 and Opportunity Assessment 2017 – 2027.” Varicella zoster infection comprises two main types namely varicella chickenpox and herpes zoster. Varicella is a highly contagious infection with an incubation period of 10–21 days, most commonly 14–16 days, after which characteristic rashes appear. Acute varicella may be complicated by secondary bacterial skin infections, cerebellitis, encephalitis, haemorrhagic complications, and viral and bacterial pneumonia. The climate is a core factor that seems to have an impact on the epidemiology of varicella. In most of the temperate climatic regions, 90% of the people are infected before adolescence. In tropical climates, VZV infection occurs later in life and adults are more susceptible to it than children.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-6466

On the other hand, herpes zoster or shingles is a sporadic disease that is caused by the reactivation of latent VZV in the sensory nerve ganglia. It is usually self-limiting and is categorised by severe pain with dermatomal distribution and at times followed by post-herpetic neuralgia that can be chronic and debilitating among the geriatric population. Though herpes zoster can occur at any age, most of the cases are reported after the age of 50 along with increasing risks of complications. In order to cater to the needs of the patients and provide a potential treatment for this infection, companies are entering into strategic partnerships in order to make use of the technology of the other leading companies and are also focussing on research and development.

For instance, in December 2016, Slayback and Sandoz signed an agreement with Novartis AG for the sale and marketing rights of Slayback Generic Zovirax Ointment (Acyclovir Ointment). Per the agreement Novartis obtained the sales and marketing rights, which increased their position in the market. Other leading companies operating in the market are Valeant Pharmaceuticals International Inc., Teva Pharmaceutical Industries Ltd, Pfizer Inc., Mylan N.V., Abbott Laboratories, GlaxoSmithKline Plc., and Dr. Reddy’s Laboratories Ltd., among others.

According to the report, the global varicella zoster infection treatment market is expected to register a 4.2% CAGR from 2017 to 2027. In 2016, the market was worth US$ 1,257.1 Mn and is expected to reach a valuation of US$ 1,969.1 Mn by the end of 2027.

Risk of Varicella in Pregnancy and the Need to Adhere to the Guidelines of Chickenpox Treatment to Bode Well for the Market

Primary infection with varicella zoster in pregnancy may cause maternal mortality or serious morbidity issues. A particular guideline issued in 2015 assesses the evidence regarding maternal and foetal risks of varicella zoster virus infection in pregnancy. The U.K. Advisory Group and Swiss and Canadian national guidelines prescribe procedures for the use of antiviral drugs in pregnancy. The U.K. Advisory Group provides guidelines for chickenpox as well. These guidelines recommend oral acyclovir, which should be prescribed for pregnant women within 24 hours once they present the onset of the rash and if they have 20+0 weeks of gestation or beyond. Guidelines are unanimous nevertheless, in recommending that intravenous acyclovir be administered in cases of severe maternal infection. This factor along with the fact that the rate of exposure and transmission is extremely high in this infection and is a threat for pregnant women and kids, is expected to boost the growth of the varicella zoster infection treatment market.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-6466 

Natural Products to Challenge Market Growth

Several people opt for other treatment options for herpes zoster and varicella. These alternative treatment options are expected to hamper the growth of the antiviral drugs market for varicella zoster infection treatment. Homeopathy, supplements, and other natural herbal medicines are used to treat herpes zoster and varicella.

Herpes Labialis Treatment Market will possibly reach beyond US$ 1.3 Bn by the end of 2027

Attributed to rising penetration of generics and innovations in disease treatment, the US$ 869.3 Mn global herpes labialis treatment market is anticipated to expand at a CAGR of 4.6% over 2017-2027, attaining a value worth US$ 1,358.7 Mn by 2027 end. Over a 10-year forecast period, the demand for herpes labialis treatment is likely to be driven by growing instances of viral infection worldwide and evolution of drug types and modes of action. Moreover, strategic M&A activities among leading industry players as well as amplifying investments in R&D ventures will also turn out to be profitable for the global herpes labialis treatment market during the assessment period.

North America to Maintain Leading Regional Market Position

Supported by strong presence of a few of the key industry players, North America’s herpes labialis treatment market is expected to continue its dominance throughout the forecast period. While this region registered over 35% value share, Western Europe recorded a share of over 20% in 2017. North American region is presumed to exceed the revenues worth US$ 450 Mn by the end of 2027, observing a declining CAGR of 3.9%. Although the US will lead the North American region, Future Market Insights projects that Canada will witness higher adoption of herpes labialis treatment in the assessment period.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-6461

On the flipside, emerging regional markets such as APEJ, MEA, Eastern Europe, and Latin America will see rapid growth in the forecast period. APEJ is identified to be the fastest growing market at a promising CAGR of 5.7%, followed by MEA, predicted to grow at 5.3% CAGR over 2017-2027. Strengthening efforts and accelerating investments in the examination of the clinical efficacy of drugs, increasing expenditure on R&D infrastructure, growing consumer awareness, and development of advanced, cost-effective treatment options at a rapid pace, will collectively lift the market in emerging countries up. Moreover, lenient FDI policies that govern the pharmaceuticals industry in developing economies prompt at the inflow of a series of opportunities for drug companies to explore these regional markets in near future.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-6461

Key Market Players

Some of the leading players competing in the global herpes labialis treatment market include Novartis AG, Valeant Pharmaceuticals International Inc., Pfizer Inc., Abbott Laboratories, Mylan NV, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and GlaxoSmithKline plc. A majority of key players are directing their efforts towards extension of existing product portfolio, while others are focusing on strategic mergers and acquisitions in order to grab larger market shares in terms of revenue. Many top brands are looking forward to capitalize on growing opportunities in emerging regional markets.

Gynaecological Examination Chairs Market Estimated to Exhibit 6.9% CAGR through 2028

With the growing income of people across the globe, they are willing to pay more for healthcare, the revenue being generated by hospitals is also increasing rapidly. Hospitals and various healthcare facilities are also increasing their spending to enhance the quality of services and their equipment. The proliferating healthcare expenditure is expected to positively impact the gynaecological examination chairs market.

As a result of the growing demand and expenditure of the consumers, companies are also gearing up in order to take leverage of the arising opportunities and to stay competent in the market. They are strengthening product portfolio by launching novel products with advanced features through product development and acquisitions and mergers. The companies are also concentrating on developing a strong distribution channel and supplier chain in order to expand their presence in the emerging and untapped markets. For instance, in May 2017, Oakworks Inc. announced the introduction of STUDIO, a table designing solution that provides clients with complete flexibility when designing products. Along this line in the same time, the company completed the collaboration with FAMED Medical Solutions. Due to collaboration the company introduce novel iNSPIRITMedical Solutions.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-6750 

According to a report published by Future Market Insights (FMI), the global gynaecological examination chairs market is expected to witness a CAGR of 6.9% from 2018 to 2028. The market was worth US$ 408.4 Mn in 2017 and is projected to rise to a valuation of US$ 852.3 Mn by the end of 2028.

Advances in Technology to Have a Positive Impact on the Market

The healthcare industry around the globe is booming exponentially. Heavy investments are made in the healthcare industry, especially in the hospital and clinics sectors. The demand for technologically advanced products is increasing among practitioners and physicians for reducing operating and examination time. Adoption of technologically advanced chairs powered by foot switches and remote will be beneficial in adjusting the required height. These advance features provide efficiency in examination. Gynaecologists across the globe are adopting advanced gynaecological chairs that are compatible with video colposcopy device holders, organic waste containers and are made of antimicrobial materials in order to reduce the time and manpower required to manage all the adjustments.

Strict Regulations to Act as a Prime Roadblock in Market Growth

The companies in the market are facing strict regulatory policies in the development of new products for medical furniture, such as examination chairs and tables. The manufactured products should meet the standards of the U.S. Access Board Proposed Standards for Accessible Medical Diagnostic Equipment. Most of the companies are facing difficulties in bringing gynaecology examination chairs to the market without greater predictability and transparency from FDA. The products have to meet the standard of sterilization and environment protection regulation.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-6750

Meningococcal Vaccines Market to Cross US$ 6,008.9 Mn by 2028

Partnerships between the private sector and public institutions have been the chief agenda of global public health initiatives. The last few years have witnessed an increase in several private-public partnerships specifically focussing on vaccine provision in developing countries. Partnerships like the International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control (ICG) help magnify the vaccine outreach to remote areas of the world with the maximum need. The governments of several countries across the globe initiate immunisation programmes periodically and these programmes are backed by global organisations such as UNICEF and WHO and private not for profits like the Global Alliance for Vaccines and Immunization (GAVI).

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1252 

A classic example of how private-public partnerships are helping boost vaccination programmes across deep regional pockets is Brazil. In 2010, Ezequiel Dias Foundation, Brazil formed a strategic alliance with Novartis Vaccines & Diagnostics for the sustainable supply of Menjugate MenC vaccines for Brazil’s National Immunization Program. By 2015, Brazil became self-sufficient in the production of the meningococcal C conjugated vaccine for the country’s public vaccination programmes. Such initiatives at the global level are anticipated to support global immunisation goals and at the same time boost growth of the meningococcal vaccines market.

Factors Leading to Worldwide Adoption of Meningococcal Vaccination Programmes

The global meningococcal vaccines market is expected to be driven by enhanced access to vaccines in low and middle-income countries, growing investments by manufacturers and governments to cope with pandemic meningitis outbreaks, and rapidly growing consumption of meningococcal vaccines bolstered by immunisation alliances and mass vaccination campaigns among others. Partnerships and alliances between manufacturers and governmental healthcare organisations are facilitating the speedy introduction of vaccines in some of the economically challenged countries of the Middle East and Africa region. Enhanced access to vaccines in under-penetrated global markets is expected to accelerate revenue growth of the global meningococcal vaccines market.

Approval of new vaccines in the U.S and Europe in 2015 and 2017 to treat meningococcal meningitis has revolutionised the global immunisation landscape. This is further boosting the growth trajectory of the global market for meningococcal vaccines.

According to Future Market Insights projections, the global market for meningococcal vaccines is expected to reach US$ 6,008.9 Mn by 2028 end from a valuation of US$ 2,290.7 Mn in 2017 – reflecting a CAGR of 9.2% during the 10 year period from 2018 to 2028.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-1252 

GlaxoSmithKline to Lead the Global Meningococcal Vaccines Market with About 50% Market Share Recorded in 2017

The global meningococcal vaccines market is highly consolidated, with GlaxoSmithKline and Sanofi together holding about 80% of the global market share in 2017. Pfizer is the third largest company in this market with just under 12% market share in 2017. Companies are expanding their production capacities through the acquisition of established vaccines production units of other global or local companies. Sanofi has a huge pipeline of 17 active meningococcal vaccines programmes and is targeting emerging markets; while GlaxoSmithKline has 5 active pipeline programmes for meningococcal vaccines, all of which are in the phase II clinical stage. Addition of the vaccine Bexsero has enabled GlaxoSmithKline to defend its brand against Sanofi’s aggressive portfolio in the paediatric vaccines space.

Orthokeratology Market Will Amass US$ 88.7 Mn by 2028

Orthokeratology has been considered to facilitate the elimination of contact lens related vision problems, providing patients with the freedom to experience an active lifestyle. While this factor will continue to play a pivotal role in growing adoption of Ortho-K lenses, Future Market Insights has discovered a few other factors that are likely to impact the growth of orthokeratology market in near future. In a recently released report, titled “Orthokeratology Market: Global Industry Analysis 2013-2017 and Opportunity Assessment, 2018–2028,” the performance of global market for orthokeratology is assessed for a 10-year period 2018-2028.

Increasing online efforts in patient education and awareness about Ortho-K, coupled with an intensifying rate of success of orthokeratology lenses in recent years, is expected to strengthen the prospects for global orthokeratology market, over the next decade. The market is likely to witness a promising CAGR of 7.4%; whereas, the global revenue is anticipated to reach beyond US$ 88 million by the end of 2028.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3142 

While increasing prevalence of myopia stands as a key factor impacting the market growth, several advantages of Ortho-K lenses over the conventional contact lenses have been recognized to be pushing adoption of orthokeratology among sports persons. A few restrictions arising in case of LASIK surgery will also be reportedly responsible for growing inclination for Ortho-K. On the flipside, the adoption of orthokeratology lenses among the myopic patient is less than 0.5%, which is a major factor deterring the growth of the market. In few under developing economies, patient are not able afford the high cost of ortho-k lenses and also the high fees of ophthalmologists and optometrists which will also deter the growth of market to some extent.

Myopia Continues to Remain the Most Influencing Indication, Accounting for a Major Revenue Share

Myopia is expected to remain a key indication driving the demand for orthokeratology, worldwide. With over 70% share of the total market value estimated for 2028, myopia will also provide an extensive scope for innovation opportunities. Hyperopia, followed by astigmatism, will represent the next key indicative factor, which is anticipated to drive market growth over the forecast period.

Demand from Optometry Clinics Accounts for a Share that Equates More than Half of the Market Value

Among all distribution channels, optometry clinics will reportedly continue to generate the maximum demand for Ortho-K, accounting for a share of more than 50% to the total market value through 2028. Ophthalmic clinics are expected to hold a decent revenue share throughout the assessment period, whereas hospitals are likely to emerge as the most opportunistic distribution channel.

Read Comprehensive Overview with Methodology of Report @ https://www.futuremarketinsights.com/askus/rep-gb-3142 

MEA Still Struggles through Low Awareness Level

North America and Europe, which represent the key regional markets, will reportedly account for a collective value share of around 60% through 2028. Asia Pacific excluding China and Japan is slated for modest growth, whereas MEA will continue to witness sluggish growth rate owing to relatively lower consumer awareness about availability and use of Ortho-K lenses.

Whole Genome Amplification Market Expected to Witness a CAGR of 7.7% through 2018-2028

A US-based team of researchers has recently developed a microfluidic device for isolating a genomic DNA, which is to be purified later. This DNA is sourced from individual cells and the device physically catches single cells using a micropillar array. It also captures chromosomal DNA of these single cells post-extraction, which is later immobilized in the micropillar array so as to enable the process of isothermal amplification. The entire methodology is referred to as ‘on-chip cell capture and DNA extraction’. As conventional single cell WGA is often prone to amplification biases, which may hold a significant influence on the accuracy of the data of single cell sequencing. This drawback is foreseen to be overcome with the introduction of single cell on-chip WGA, resulting in reduced biases regarding amplification, offering an improved coverage of the genome. The team has used individual cancer cell genomes (human), sourced from the HeLa Cell Line.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1873 

WGA has been a crucial procedure that helps in DNA analysis from limited quantities of genomic DNA. The ease provided by various WGA kits available for the entire process has been driving the market over the years. Increasing research activities will remain the key factor pushing the growth of whole genome amplification market over the next decade. Adoption of this process is expected to witness robust growth, predominantly among research institutes, hospitals, diagnostic centers, and forensic labs, as it offers an improved and advanced means of genome amplification and sequencing.

To increase the revenue share, molecular testing companies are focusing more on the development of advanced devices and kits such as WGA kits and complete WGA kits with advanced capabilities. The global whole genome amplification market is estimated at around US$ 4 million by the end of 2028, as indicated by a recent report released by Future Market Insights. The global market for whole genome amplification will possibly expand at a CAGR of 7.7% during the forecast period, 2018-2028.

Single Cell WGA Continues to Bring in New Applications

Introduction of massively parallel single-cell genome sequencing is anticipated to offer a new dimension to the understanding of genetic diversities in complex biological systems. Single cell WGA is a method used to examine the sequence information with the optimized next generation sequencing technologies, only from a single cell. This method is considered to be a powerful tool that helps to understand the ins and outs of genetics by bringing the entire genome structure to a cellular level. Since this method offers a high-resolution view of the genomic sample, its adoption will continue to be on the rise in diverse biological fields such as microbiology, immunology, neurobiology, cancer research, and tissue mosaicism. Single cell WGA also plays a crucial role in conveying new applications to the market, eventually pushing the market growth further through 2028.

New Technology Assessment in Branded WGA Products

As a move towards better results and implementation of advanced technology, novel techniques are being introduced in the new WGA products. The TruePrime Single Cell WGA Kit (Expedeon Ltd.), utilizes a unique and reliable method to achieve accurate genome amplification from single cells. TruePrime technology uses a revolutionary novel multiple displacement amplification (MDA) method based on the combination of the recently discovered DNA primase “TthPrimPol” and the extremely processive and high-fidelity Phi29 DNA polymerase to amplify uniformly total genomic DNA either a single or a few cells. Similarly MALBAC Multiple annealing and Looping Based Amplification Cycles) technology and PicoPLEX® WGA kit (Rubicon Genomics), with patented technology are the other options that have been unveiled as the latest and advanced technologies which are more efficient and optimized in the results and analysis outcomes.

Companies Focusing on Better Product Quality through Life Science Research

Increasing prevalence of infectious diseases and oncology disorders has increased the demand for WGA devices and kits, fueling the growth of companies dealing in WGA kits. Despite the market having several large players as well as multiple smaller companies, there are limited companies that have a complete focus on being a provider of life science products and reagents. Vendors have different specializations and product offerings, with most of the large companies combining research products and reagents with equipment, in-vitro diagnostics tools etc. However, the companies that have a sole focus on this market can have better growth prospects in the coming future. They can ensure better quality of products, customer loyalty and an established distribution network that can cater to product availability around the globe.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-1873 

The key players of the market, including GE Healthcare, Sygnis AG, Illumina, Inc., Merck KGaA, Thermo Fisher Scientific Inc., and Active Motif are inclined more towards strategic acquisitions and mergers. They are also looking for distribution and collaboration agreements to help improve their product reach. It will also help them serve end users better, with diagnostic consulting and good laboratory practices. High price point may remain a major challenge for companies.

Muscle Stimulation Devices Market Will hit at a CAGR of 3.9% from 2018 to 2028

Application of Novel Nerve Stimulation Device to Offer New Dimension to Stroke Care, Improving Overall Quality of Life

The performance of the global muscle stimulation devices market is expected to witness immensely impactful developments, with potential improvements in the recovery of stroke through nerve stimulation. With rising rate of AIS (acute ischemic stroke), the focus has been shifted to improving the associated stages of stroke care, including prevention, intervention, and rehabilitation. The Ohio State University has been conducting a new clinical trial to shorten the motor skills recovery period in stroke patients, via VNS (vagus nerve stimulation).

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1140 

The trial involves the use of a device – Vivistim, which has been developed by MicroTransponder, a Dallas-based company. The device functions by coupling VNS with the muscle movement, during rehabilitation. It is supposed to build up the motor function, learning, and memory, drastically improving the post-stroke outcome thereby. This nerve stimulation therapy, if used in tandem with appropriate interventions, can potentially result in excellent rehabilitation, minimizing the impact of complications that may follow the treatment process. If Vivistim delivers positive results and enables stroke patients to regain their motor function early, the market participants may witness multiple doors of opportunities in the rehabilitative treatment area.

Key Companies to Focus on Strong Distribution Channel Development & Suppliers to Strengthen Presence in Emerging Markets

New and innovative product launches such as wireless devices are being considered by manufacturers as the key to achieve enhanced device capabilities, which is presumed to trigger sales in long term. To expand market shares and improve distribution network through the next decade, several players are prioritizing strategic partnerships, i.e. distribution agreements for their product offerings. Enhanced distribution will also help the stakeholders penetrate various untapped regional markets.

Key players in the global muscle stimulation devices market are focusing on development of new pain management methods and techniques. Adoption of innovative marketing strategy by muscle stimulation device manufacturers is attributed to their gradually increasing market value share. Increased focus on strengthening of distribution channel will reportedly be the key for market expansion in emerging economies. On the flipside, suppliers are likely to consider patient needs as a top priority, while ensuring the supply of high-quality products to end users. Stakeholders are strengthening product portfolio by launching new products with improved features, and through strategic mergers and acquisitions. Moreover, a growing number of local players in the muscle stimulation devices market is expected to result in creating a fragmented market, since the market is already led by smaller-sized firms catering to domestic customer demands.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-1140 

Muscle Stimulation Devices to Face Passive Growth

Despite immense scope for innovation in product development and applications, the global market for muscle stimulation devices is projected to observe sluggish growth over the next decade. As prompted by a recent research study by Future Market Insights, the global muscle stimulation devices market will expand at a CAGR of 3.9% during 2018-2028, attaining a value of over US$ 870 Mn by 2028 end. High price point will remain a longstanding factor limiting widespread adoption of muscle stimulators. Stringent regulatory norms regarding the launch and use of muscle stimulation devices is also anticipated to hinder market growth in upcoming decade.

By value, North America and Western Europe are expected to represent the dominant markets for muscle stimulation devices, whereas developing economies such as APEJ, Latin America, and Eastern Europe will reportedly exhibit relatively promising performance over the projection period.

Pulmonary Arterial Hypertension Treatment Market Poised to Reach US$ 6.5 billion in terms of revenue by 2028

Owing to non-responsive nature of several advance pharmacotherapies and high diagnosis and treatment costs, researchers and medical practitioners in the global pulmonary arterial hypertension treatment market are continually working on favorable and effective alternative treatment models and increase survival rate among the patients with pulmonary arterial hypertension.

Future Market Insights, in its recently published outlook on the global market for pulmonary arterial hypertension treatment market, projects the US$ 5 billion market to barely exceed US$ 6.5 billion in terms of revenue, through the next decade. The market has been estimated at a sluggish CAGR of 2.5% over 2018-2028. However, innovations and combination therapeutics are likely to forestall further decline of the pulmonary arterial hypertension treatment market in near future.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-1218 

Cancer Protein Molecules Tested for Potential Therapeutic Use- to Prevent Pulmonary Arteries ‘Scarring’

Scarring or Fibrosis, in pulmonary arterial hypertension, is an important cause of damage to pulmonary arteries, which in turn, strains the heart functions- eventually leading to breathlessness. Recently, researchers from Brigham and Women’s Hospital conducted a study using network medicine- a method of establishing correlation between proteins, pathways and more- and identified the cancer protein NEDD9 and its molecular mechanisms as a potential treatment for PAH patients. The study has identified that a specific amino acid residue in the cancer protein is expected to play a crucial role in controlling and regulating the severe consequences of scarring.

BH4- Factor Controlling Production of Nitric Oxide- Shows Promising Result on Rat Model; Results Show Lower Lung Hypertension

Researchers at Imperial College London and Bar-Ilan University, Israel explored the properties of naturally occurring tetrahydrobiopterin (BH4) and its subsequent role in effective treatment for lung hypertension and right heart failure. BH4 controls the production of endothelial nitric oxide synthase (eNOS) in the human body. eNOS produces nitric oxide which is important for healthy endothelial cells- forming the inside lining of blood vessels. Nitric oxide is responsible for dilating blood vessels, working to lower lung blood pressure.

The study- conducted on a rats first in injected with chemical triggering pulmonary hypertension and then an injection of BH4, showed signs of decreased lung pressure, stronger heart contractions and, enlarged heart.  The rats were then given BH4 in food before the chemical that previously induced pulmonary hypertension. As a result of which, no thick layers of smooth muscles were developed- often leading to lung hypertension.

After the phase 1 of clinical trials, the patients- administered BH4 orally, showed improved exercise capacity- an indicator of low pressure in lungs. It is anticipated that BH4, when given controlled measure could prove to a valuable treatment for pulmonary arterial hypertension patients who otherwise are not responsive to regular medication.

Read Comprehensive Overview with Methodology of Report @ https://www.futuremarketinsights.com/askus/rep-gb-1218 

With Treatment Options, ‘Accurate Risk Measuring’ Tools is the Need of the Hour

Although measurable efforts are being made in the global pulmonary arterial hypertension treatment market, the survival rate among PAH patients continues to remain low.  According to studies, the average life expectancy of PAH patient is approximately 3 years from symptom onset- being at a risk of disease progression and frequent hospitalizations. Several studies indicate that early diagnosed and ‘low-risk’ patients stand a chance of improved survival if the risk is calculated accurately. Experts have expressed the need to develop appropriate and accurate risk prediction tools improve treatment outcomes in PAH patients.

Drug Designing Tools Market to Reach US$ 5,150.1 Mn by 2028

The global drug designing tools market is expected to grow from US$ 1,777.3 Mn in 2018 to US$ 5,150.1 Mn by 2028, expanding at a CAGR of 11.23% in terms of revenue during the forecast period (2018-2028). In a new report by Future Market Insights, the global drug designing tools market is tracked in terms of value and is calibrated to obtain the market revenue estimates. The adoption of advanced technologies in drug designing tools and increasing requirement of time- and cost-effective tools are boosting growth of the drug designing tools market. However, infrastructure compatibility is a major problem faced by most organizations and is likely to challenge revenue growth of the global drug designing tools market.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3806 

To understand and assess the demand and opportunities in the drug designing tools market, the report is categorically split into four major sections that focus on market analysis by solutions, by application, by end user, and by region.

The section – market analysis by solutions comprehensively analyses the market on the basis of multi databases, virtual screening tools, structure designing/building tools, predictive analytics, model building tools, and other solutions in terms of value for the period 2018-2028. In 2018, the multi databases segment dominated the drug designing tools market, followed by the virtual screening tools segment. The predictive analytics segment is projected to expand at the fastest CAGR of 13.22% over the forecast period in the drug designing tools market in terms of revenue, followed by the virtual screening tools segment.

The section – market analysis by application, analyses the various applications that use drug designing tools, and the data is provided in terms of value for 2018-2028. The binding site prediction segment is expected to expand at a significant CAGR of 12.75% in terms of value during the forecast period. In terms of market share, the docking segment accounted for a major percentage of the revenue share of the overall market in 2017, and is expected to dominate the drug designing tools market throughout the forecast years, followed by the target prediction segment.

The section – market analysis by end user, analyses various users that use tools in research and development, and the data is provided in terms of value for 2018-2028. The contract research organisations segment is expected to expand at a significant CAGR of 11.99% in terms of value during the forecast period. In terms of market share, the pharmaceutical companies segment accounted for a major percentage of the revenue share of the overall market in 2017, and is expected to dominate the drug designing tools market throughout the forecast years, followed by the biotechnology companies segment.

Read Comprehensive Overview with Methodology of Report @ https://www.futuremarketinsights.com/askus/rep-gb-3806 

The section – market analysis by region includes an in-depth country-level analysis of the key regions in the world, namely, North America, Latin America, Western Europe, Eastern Europe, SEA & Others of APAC, China, Japan, and Middle East & Africa by product type, end user, and countries; and provides market data in terms of value for the forecast period 2018-2028. In 2018, the market in North America dominated the overall global drug designing tools market, followed by the market in Western Europe.

Bioprocessing Analytics Equipment Market will Register a CAGR of 4.5% through 2028

Future Market Insights (FMI) delivers key insights on the global bioprocessing analytics equipment market in an upcoming report titled “Bioprocessing Analytics Equipment Market: Global Industry Analysis 2013–2017 and Opportunity Assessment 2018 – 2028”. In terms of revenue, the global bioprocessing analytics equipment market is anticipated to register a CAGR of 4.5% over the forecast period, owing to various factors, regarding which FMI offers detailed insights and forecasts in this report.

Bioprocessing Analytics Equipment Market: Segmental Analysis

The global bioprocessing analytics equipment market is segmented based on product type, application, end user and region. Based on product type the market is segmented into osmometers and bioprocess analysers. Osmometers is the leading product type in the bioprocessing analytics equipment market over the forecast period.  North America is expected to gain popularity over the forecast period, driven by cell-based bioprocesses extensively utilised for therapeutics protein production. Manual monitoring of such bioprocesses is labour intensive and can lead to errors in the production process.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5405 

Due to rapid advancements in technology, manufacturers have developed integrated multi-functional analysers, which combine the functionality of different single analyzers (like cell counters, osmometers, nutrient/electrolyte/metabolite bio-profile analyzers) into one technologically enabled novel sampling system to analyse the culture medium automatically. The integration of multiple functionality allows feedback control of parameters and reduces error rates in bioprocessing.

The market is further categorised based on application into clinical and industrial applications. The industrial application segment is expected to lead in the global bioprocessing analytics equipment market during the assessment period. Demand for bioprocessing analytics equipment is anticipated to be the highest across various industries, and the industrial segment is projected to register a CAGR of 4.4% over the forecast period.

The market is further classified based on end users. End user segments include Biopharmaceutical Companies, Contract Research Organization (CROs), Contract Manufacturing Organizations (CMOs), Academics & Research Institutes, and Clinical Diagnosis. Biopharmaceutical companies are the largest end users of bioprocessing analytics equipment while demand for bioprocessing analytics equipment is expected to be the highest in Biopharma companies – anticipated to register a growth rate of 3.9% over the forecast period.

Bioprocessing Analytics Equipment Market: Regional Forecast

This report assesses trends that are driving the growth of each market segment at the global as well as regional level, and offers potential takeaways that could prove substantially useful to manufacturers looking to enter the market. The North America market is estimated to dominate the global bioprocessing analytics equipment market, accounting for a maximum revenue share of the market by 2018 end. The Western Europe and APECJ markets are collectively expected to account for around 39.2% of the total bioprocessing analytics equipment market share in terms of value by 2018 end. Revenue from the market in APECJ is projected to expand at a CAGR of 5.9% over the forecast period.

Read Comprehensive Overview with Methodology of Report @ https://www.futuremarketinsights.com/askus/rep-gb-5405 

A key trend witnessed in the bioprocessing analytics equipment market is product innovation. Furthermore, the growing importance of developing bioprocessing analytics equipment by big players to enhance their product portfolio is trending the global bioprocessing analytics equipment market.

Compostable & Biodegradable Refuse Bags Market to grow at a CAGR of 8.0% through 2028

Future Market Insights (FMI) delivers key insights on the global compostable & biodegradable refuse bags market in its published report, titled “Global Compostable & Biodegradable Refuse Bags Market: Industry Analysis and Opportunity Assessment 2018–2028”. In terms of revenue, the global compostable & biodegradable refuse bags market is estimated to expand at a CAGR of 8.0% over the forecast period, owing to numerous factors, about which FMI offers thorough insights and forecasts in this report.

Compostable & biodegradable are terms used to designate organic materials breaking down in specific environment condition. Refuse bags are disposable bags used to contain waste and rubbish. Compostable & biodegradable refuse bags are made up of organic material, which are obtained from plants. Such plant based materials which are used to make compostable & biodegradable refuse bags are starch blends (corn, potato and others), Polylactic acid (PLA), PHA, PBAT and other such materials. These refuse bags can undergo decomposition readily and have minimum negative impact on the environment.

The global market for compostable and refuse bags market is further segmented as per capacity, product type, speed, material type, thickness and end use.

On the basis of capacity type, global market for compostable & biodegradable refuse bags is segmented into 7-20 gallons, 20-30 gallons, 30-40 gallons, 40-55 gallons and above 55 gallons. On the basis of product type, global market for compostable & biodegradable refuse bags is segmented into biodegradable and compostable. On the basis of material type, global market for compostable & biodegradable refuse bags is segmented into PLA, PBS, PBAT, PHA, starch blends, cellophane and paper. On the basis of thickness, the global market for compostable & biodegradable refuse bags is segmented into 0-0.7 mil, 0.7-0.9 mil, 0.9-1.5 mil, above 1.5 mil. On the basis of end use, the global market for compostable & biodegradable refuse bags is segmented into retail and consumer, industrial and institutional.

This report assesses trends driving the growth of each market segment on the global level and offers potential takeaways that prove substantially useful for other potential market entrants in the compostable & biodegradable refuse bags market.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-7082 

The North America compostable & biodegradable refuse bags market Include country level analysis for the U.S. and Canada. The U.S compostable & biodegradable refuse bags market is expected to grow at a CAGR of 7.7% over the forecast period wherein compostable segment enjoy dominant share, by product type. The Latin America compostable & biodegradable refuse bags market include country level analysis for Brazil, Mexico, Argentina and Rest of Latin America. The Brazil compostable & biodegradable refuse bags market is expected to expand at a CAGR of 7.5% during the forecast period. The Western Europe compostable & biodegradable refuse bags market include country level analysis for Germany, Italy, U.K., France, Spain, Benelux, Nordic and Rest of Europe. Germany and Italy account for a significant market share in the Western Europe compostable & biodegradable refuse bags market. 

The Eastern Europe compostable & biodegradable refuse bags market include country level analysis for Russia, Poland and Rest of Eastern Europe. The Russia compostable & biodegradable refuse bags market is expected to expand at a CAGR of 7.6% during the next decade. The Asia Pacific excluding Japan compostable & biodegradable refuse bags market includes country level analysis for China, India, ASEAN, Australia & New Zealand and Rest of APEJ. The APEJ compostable & biodegradable refuse bags market represent most lucrative geographic region wherein India and China represent substantial incremental opportunity over the forecast period. The Middle East and Africa (MEA) compostable & biodegradable refuse bags market include country level analysis for GCC, South Africa, North Africa and Rest of MEA. Compostable & biodegradable refuse bags market in the GCC region is particularly driven by high growth in the industrial segment. The Japan compostable & biodegradable refuse bags market is expected to expand at a CAGR of 5.3% over the forecast period.

In this report, we have discussed individual strategies followed by these companies in terms of enhancing their product portfolio, creating new marketing techniques, mergers and acquisitions. The ‘Competitive Landscape’ is included to provide report audiences with a dashboard view and company share collectively.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-7082 

Key players operating in the global market for compostable & biodegradable refuse bags include Mondi Group, Sphere Group, Vegware Global, VICTOR Güthoff & Partner GmbH, Cedo Ltd., BioBag International AS, PLAST-UP, Polybags Ltd, Clondalkin Group Holdings B.V., Plastiroll Oy Ltd, The Biodegradable Bag Company Ltd, QUICKPACK Haushalt + Hygiene GmbH, MIRPACK, TM, The Compost Bag Company, SIMPAC, TERDEX GmbH, Pack-It BV, Cromwell Polythene Ltd, Flexopack SRL, Virosac SRL among others.

Behavioural Health Market Highly Favorable to the Growth Rate by 2028

According to the latest market report published by Future Market Insights titled “Behavioural Health Market: Global Industry Analysis 2013–2017 and Opportunity Assessment 2018–2028”, the global behavioural health market is expected to expand at 3.4% CAGR over the forecast period 2018-2028.

North America is expected to hold the highest revenue share in the global behavioural health market over the forecast period. Currently, over 43.8 million adults in the U.S. are suffering from mental illness, which is fuelling demand for behavioral health services. Developing economies are witnessing large demand for home care services, day care services, and internet-counselling services, which is further expected to boost revenue growth of the behavioural health market in emerging markets.

Request to View Sample of Research Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5375 

Global Behavioural Health Market: Segmental Analysis & Forecast

The global behavioural health market is segmented based on service type, disorder type, and region. Based on service type the market is segmented into outpatient counselling, intensive case management, home-based treatment services, inpatient hospital treatment, emergency mental health service and others. The inpatient hospital treatment services type segment is expected to represent highest revenue share in the global behavioural health market. Home-based treatment services are expected to gain popularity among people in the coming years and this segment is expected to expand at a CAGR of 4.0% over the forecast period.

Based on disorder type the market is segmented into the anxiety disorder, bipolar disorder, depression, eating disorder, post-traumatic stress disorder (PSTD), substance abuse disorder and others. Among all disorder types, the anxiety disorder segment is anticipated to continue to lead the global behavioural health market due to a high patient pool globally and high adoption of behavioural health therapy among patients suffering from anxiety issues. According to the WHO, globally 260 million people are suffering from anxiety disorder.

Increased exposure to drugs and alcohol among young adults and strengthening insurance coverage policies for mental health are identified as key trends among end users in the global behavioural health market. Furthermore, rehabilitation programs for substance abuse disorder patients, outpatient counselling for ADHD affected children, and campaigns to spread awareness regarding mental disorders and drug addiction, etc. are some of the major factors that are driving the growth of the global behavioural health market. Government initiatives to reduce the burden of mental illness and rehabilitation services by non-government organizations (NGO) are further expected to positively impact revenue growth of the global behavioural health market.

Request Report for Table of Contents @ https://www.futuremarketinsights.com/askus/rep-gb-5375 

Global Behavioural Health Market: Competition Analysis

The global market for behavioural health is fragmented with many local and regional level players operating in the worldwide market. Some of the key players featured in the global behavioural health market report include Acadia Healthcare Co., Inc., Universal Health Services Inc., Magellan Health Inc., National Mentor Holdings Inc., Behavioral Health Services Inc., Behavioral Health Network Inc., North Range Behavioral Health, Strategic Behavioral Health LLC, Seton Healthcare Family (Ascension Health) and Ocean Mental Health Services Inc. etc. among others.